指南与共识白血病

Ferrara标准预测强化疗后早期死亡准确性

Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
指南 / 共识 · J Clin Oncol · 2020-10-08

该研究评估了Ferrara不适宜标准对接受强化疗的AML或高危髓系肿瘤成人患者早期死亡和生存的预测准确性。655例患者中30%符合不适宜标准,其总生存显著缩短(中位4.8个月 vs 36.8个月),该标准预测第28天和第100天死亡的AUC分别为0.76和0.79,加入体能状态和白蛋白后可提高至0.84-0.85。

要点

  • Ferrara标准可较好预测强化疗后短期死亡,AUC 0.76-0.79。
  • 符合不适宜标准者总生存显著缩短(中位4.8 vs 36.8个月)。
  • 加入体能状态和白蛋白可提高预测准确性至AUC 0.84-0.85。

核心结论

  • Ferrara不适宜标准是预测AML强化疗后短期死亡的良好工具。

研究设计与样本

  • 研究纳入655例接受强化疗的成人AML或高危髓系肿瘤患者,依据Ferrara标准评估不适宜性并分析预测准确性。

主要发现

  • 655例中197例(30%)符合至少一项不适宜标准(F-unfit)。
  • F-unfit患者总生存显著短于F-fit患者(中位4.8个月,95%CI 3.6-6.5 vs 36.8个月,95%CI 27.4-73.0,P<.001)。
  • Ferrara标准预测第28天和第100天死亡的AUC分别为0.76和0.79,优于既往治疗相关死亡率评分(AUC 0.66和0.62)。
  • 加入体能状态和白蛋白后,预测第28天或第100天死亡的AUC可高达0.84-0.85。
  • 多变量模型预测总生存的c-statistic最高为0.75。

关键数值与推荐

  • Ferrara不适宜标准预测第28天死亡AUC 0.76,第100天死亡AUC 0.79。
  • 加入体能状态和白蛋白后AUC提高至0.84-0.85。

临床怎么用

  • 可用Ferrara标准识别不适合强化疗的AML患者,辅助治疗决策。
  • 结合体能状态和白蛋白可提高早期死亡预测准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With increasing therapeutic alternatives available, there is growing interest in tools that accurately identify patients most suitable for intensive acute myeloid leukemia (AML) chemotherapy. Nowadays, conceptual criteria proposed by an Italian panel of experts are widely used for this purpose. How accurately these Ferrara criteria predict fitness for intensive chemotherapy is unknown. PATIENTS AND METHODS: We assessed the fitness of adults undergoing intensive AML therapy based on Ferrara criteria and determined the accuracy of this assessment for early mortality and survival prediction. RESULTS: Among 655 adults who received curative-intent induction or reinduction chemotherapy with 7 days of standard-dose cytarabine and 3 days of an anthracycline ("7+3") CLAG-M (cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone), or reduced-dose CLAG-M, 197 (30%) met at least one of the criteria defining unfitness for intensive chemotherapy (F-unfit). Compared with F-fit patients, the overall survival of F-unfit patients was significantly shorter (median, 4.8 months; 95% CI, 3.6 to 6.5 months v 36.8 months; 95% CI, 27.4 to 73.0 months; P < .001). When used alone, the Ferrara unfitness assessment was more accurate in predicting day 28 and day 100 mortality than the treatment-related mortality score we developed previously (used binary, ≤ 13.1 v > 13.1), as indicated by area under the receiver operating characteristic curve (AUC) values of 0.76 and 0.79 versus 0.66 and 0.62. The predictive accuracy of the Ferrara unfitness assessment could be significantly improved by including additional covariates such as performance status and albumin, yielding AUCs as high as 0.84-0.85 for the prediction of day 28 or day 100 mortality. Prediction of overall survival was less accurate, yielding a c-statistic value as high as 0.75 in multivariable models. CONCLUSION: Ferrara unfitness criteria provide a good prediction tool for shorter-term mortality after intensive AML chemotherapy. Our data may serve as a benchmark for expected outcomes with intensive chemotherapy in F-fit and F-unfit patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Palmieri R, Othus M, Halpern AB, et al. Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. J Clin Oncol. 2020. PMID: 33030979. doi:10.1200/JCO.20.01392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。